LSE - Delayed Quote GBp

Oxford Biomedica plc (OXB.L)

296.00

+6.00

+(2.07%)

At close: May 15 at 4:38:03 PM GMT+1

High Growth Tech Stocks In The UK For May 2025

The United Kingdom's market has recently faced challenges, with the FTSE 100 index experiencing a decline due to weak trade data from China, highlighting concerns about global economic recovery and its impact on UK companies tied to international markets. In this environment, identifying high growth tech stocks requires focusing on companies that demonstrate resilience and adaptability in the face of fluctuating global conditions.

Simply Wall St. 3 days ago

OXBDF

RPBPF

RCN.L
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Oxford, UK – 9 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from 13–17 May 2025 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The Company will exhibit at Booth #1611, where delegates can meet OXB’s tea

GlobeNewswire 6 days ago

OXBDF
Oxford Biomedica Full Year 2024 Earnings: EPS Beats Expectations

Oxford Biomedica ( LON:OXB ) Full Year 2024 Results Key Financial Results Revenue: UK£128.8m (up 44% from FY 2023). Net...

Simply Wall St. 14 days ago

OXBDF
Exploring Redcentric And 2 Other High Growth Tech Stocks In The UK

The United Kingdom's market landscape has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting concerns over global economic recovery and its impact on UK companies. In this environment, identifying high-growth tech stocks like Redcentric becomes crucial as investors seek opportunities that can withstand external pressures and capitalize on technological advancements within the UK's evolving market.

Simply Wall St. last month

RPBPF

RCN.L

OXBDF
Oxford BioMedica PLC (OXBDF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...

Oxford BioMedica PLC (OXBDF) reports a 44% revenue increase and significant EBITDA improvement, while navigating market challenges and expanding its European footprint.

GuruFocus.com last month

OXBDF
When Will Oxford Biomedica plc (LON:OXB) Turn A Profit?

We feel now is a pretty good time to analyse Oxford Biomedica plc's ( LON:OXB ) business as it appears the company may...

Simply Wall St. last month

OXBDF
Preliminary results for the year ended 31 December 2024

~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1Operating EBITDA2 loss of £(15.3) million for the full year in line with expectations, Operating EBITDA profit of £5.0 million achieved in second half of 2024 Contracted value of client orders3 signed during 2024 reached approximately £186 million at 31 December 2024, an increa

GlobeNewswire last month

OXBDF
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards. The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global bi

GlobeNewswire last month

OXBDF
OXB to present at the Leerink Partners Global Healthcare Conference

OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday, 11 March 2025 at 2:20 PM EDT / 6:20 PM GMT. A live webcast of the fireside chat will be available on the ‘Investor Relations’ section of

GlobeNewswire 2 months ago

OXBDF
Boehringer and partners commence gene therapy trial for cystic fibrosis

The Phase I/II trial will assess the therapy’s tolerability, efficacy and safety.

Clinical Trials Arena 2 months ago

OXBDF
High Growth Tech Stocks In The United Kingdom Featuring Beeks Financial Cloud Group

The United Kingdom's stock market has been experiencing some turbulence, with the FTSE 100 closing lower due to weak trade data from China, highlighting the challenges faced by companies tied to global economic conditions. In this environment, identifying high-growth tech stocks can be particularly appealing as they often demonstrate resilience and potential for significant returns despite broader market uncertainties.

Simply Wall St. 2 months ago

GBGPF

OXBDF

BKS.L
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of LENTICLAIR™ 1 trial, utilising OXB lentiviral vectors; builds on long term collaboration with Boehringer Ingelheim Oxford, UK – 20 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that its proprietary lentiviral vector manufacturing technology will be use

GlobeNewswire 2 months ago

OXBDF
Appointment of Joint Corporate Broker and Joint Financial Adviser

Oxford, UK – 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint Corporate Broker and Joint Financial Adviser, to work alongside RBC Capital Markets, with immediate effect. -Ends- Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare:T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott /

GlobeNewswire 3 months ago

OXBDF
High Growth Tech Stocks In The United Kingdom January 2025

As the UK market grapples with the ripple effects of faltering trade data from China, reflected in the recent declines of both the FTSE 100 and FTSE 250 indices, investors are closely monitoring how these global economic challenges impact sectors reliant on international demand. In this environment, identifying high-growth tech stocks that demonstrate resilience through innovative solutions and robust business models becomes crucial for navigating potential market volatility.

Simply Wall St. 3 months ago

IFJPY

IFPJF

GBGPF
High Growth Tech Stocks In The UK To Watch December 2024

The United Kingdom's market has recently experienced a downturn, with the FTSE 100 and FTSE 250 indices closing lower amid weak trade data from China, highlighting ongoing global economic challenges. In this environment, identifying high growth tech stocks that can navigate such volatility becomes crucial, as these companies often possess innovative solutions and robust business models that may offer resilience against broader market pressures.

Simply Wall St. 4 months ago

IFJPY

IFPJF

OXBDF
Exploring High Growth Tech Stocks in the UK for November 2024

The United Kingdom's market has recently experienced a downturn, with the FTSE 100 closing lower due to weak trade data from China, highlighting concerns over global economic recovery and its impact on commodity-dependent sectors. In this challenging environment, identifying high-growth tech stocks in the UK requires focusing on companies that demonstrate resilience and innovation, as they are better positioned to navigate economic uncertainties and capitalize on emerging opportunities.

Simply Wall St. 5 months ago

OXBDF

IFJPY

IFPJF
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development

OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces it will host a free 60-minute webinar exploring how advanced robotics can be used to speed up the development of viral vector drug products. The webinar titled "Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Re

GlobeNewswire 5 months ago

OXBDF
High Growth Tech Stocks In The UK October 2024

In the last week, the United Kingdom market has remained flat, although it has experienced a 12% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth and positive forecasts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to capitalize on emerging opportunities within this dynamic sector.

Simply Wall St. 6 months ago

PDGNF

SAA.L

OXBDF
Exploring Three High Growth Tech Stocks in the United Kingdom

In the current UK market landscape, the FTSE 100 has recently experienced declines due to weak trade data from China, highlighting global economic interdependencies and their impact on local indices. As investors navigate these challenges, identifying high-growth tech stocks in the United Kingdom requires a focus on companies that demonstrate resilience and innovation amidst broader market volatility.

Simply Wall St. 6 months ago

OXBDF

SAA.L

PDGNF
High Growth Tech Stocks In The UK Featuring Keywords Studios And Two More

The UK market has faced challenges recently, with the FTSE 100 index experiencing a decline following weak trade data from China, highlighting concerns over global economic recovery and its impact on commodity-linked companies. In this environment, high-growth tech stocks such as Keywords Studios offer potential opportunities for investors seeking resilience and innovation amidst broader market uncertainties.

Simply Wall St. 6 months ago

OXBDF

KYYWF

KYYWY

Performance Overview

Return	OXB.L	FTSE 100 (^FTSE)
YTD	-29.52%	+5.64%
1-Year	-8.07%	+2.23%
3-Year	-40.80%	+16.39%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oxford Biomedica plc (OXB.L)

High Growth Tech Stocks In The UK For May 2025

OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Oxford Biomedica Full Year 2024 Earnings: EPS Beats Expectations

Exploring Redcentric And 2 Other High Growth Tech Stocks In The UK

Oxford BioMedica PLC (OXBDF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...

When Will Oxford Biomedica plc (LON:OXB) Turn A Profit?

Preliminary results for the year ended 31 December 2024

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

OXB to present at the Leerink Partners Global Healthcare Conference

Boehringer and partners commence gene therapy trial for cystic fibrosis

High Growth Tech Stocks In The United Kingdom Featuring Beeks Financial Cloud Group

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis

Appointment of Joint Corporate Broker and Joint Financial Adviser

High Growth Tech Stocks In The United Kingdom January 2025

High Growth Tech Stocks In The UK To Watch December 2024

Exploring High Growth Tech Stocks in the UK for November 2024

OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development

High Growth Tech Stocks In The UK October 2024

Exploring Three High Growth Tech Stocks in the United Kingdom

High Growth Tech Stocks In The UK Featuring Keywords Studios And Two More

Performance Overview